Ekf Diagnostics Holdings Plc · LSE:EKF

Ekf Diagnostics — H1 2018 Earnings Presentation

9 slides from Ekf Diagnostics's earnings presentation, Sep 19, 2018

  1. Slide 1: Financial results for six months ended 30 June 2018

    Financial results for six months ended 30 June 2018 19 September 2018

  2. Slide 2: Disclaimer

    Disclaimer This presentation is the sole responsibility of the directors of EKF Diagnostics Holdings plc (the “Company”). Nplus1 Singer Advisory LLP (“N+1 Singer”), which is authorised and regulated by the Financial Conduct Authority, is acting as the nominated adviser and broker to the Company. Thi

  3. Slide 3: Agenda

    Agenda Slide no. 4. Financial highlights 5. Operational highlights 6. Income statement: Extract 7. Statement of financial position: Extract 8. Outlook

  4. Slide 4: Financial Highlights

    Financial Highlights 2012 2013 2014 2015 • Adjusted EBITDA* up 7% to £4.90m (H1 2017: £4.58m) 2016 2017 2018 • Revenues in-line year-on-year on a constant currency basis at £21.20m (H1 2017: £21.50m) • 4.90 Reported revenues of £20.36m, impacted by exchange rates 4.58 • Strong cash generation from o

  5. Slide 5: Operational Highlights

    Operational Highlights • DiaSpect Tm has received FDA 510k CLIA clearance • OEM contract with McKesson – Surgical Inc. • Exclusive rights for distribution of DiaSpect Tm in all US markets except blood banks, driving further US sales growth following November 2018 product launch • Substantial revenue

  6. Slide 6: Income Statement: Extract

    Income Statement: Extract H1 2018 £k H1 2017 £k +/- £k Revenue 20,357 21,498 (1,141) Gross profit 10,991 11,839 (848) GM % 54% 55% (-1%) Admin. costs (9,099) (10,163) 1,064 Other income 21 19 2 Operating profit 1,913 1,695 218 AEBITDA 4,897 4,577 320 6

  7. Slide 7: Statement of Financial Position: Extract

    Statement of Financial Position: Extract H1 2018 £k H1 2017 £k +/- £k Intangible assets 42,624 45,165 (2,541) Property, plant, equipment 12,329 12,096 233 Investments 152 152 - Inventories 5,563 5,638 (75) Trade / other receivables 7,896 9,366 (1,470) Cash and cash equivalents 9,925 5,719 4,206 Defe

  8. Slide 8: H2 and 2019 Outlook

    H2 and 2019 Outlook • Growth opportunities from new registrations, new products and customers: – McKesson OEM of DiaSpect Tm. First shipments Q4 2018 – Incremental growth from Life Sciences following capital investment in additional fermenters and strong order book – Launch of Lactate Scout 4.0 in Q

  9. Slide 9: Thanks for your attention

    Thanks for your attention

EKF Diagnostics Holdings — H1 2018 Earnings Presentation on 6ix